Here are 40 books that The Billion-Dollar Molecule fans have personally recommended if you like
The Billion-Dollar Molecule.
Book DNA is a community of 12,000+ authors and super readers sharing their favorite books with the world.
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
Since Nixon’s "War on Cancer," oncology treatment has seen some great advances, but also the approval of scores of over-priced drugs that do little to improve patients’ quality or quantity of life. Oncologist Vinay Prasad has written a broad, accessible overview of the flaws of modern cancer drug development that spans clinical trial design, conflicts of interest, regulatory policy, and more. His unabashedly anti-pharma stance gets preachy in places, but most of the challenges he identifies are spot-on and provide a thought-provoking roadmap for the future.
How hype, money, and bias can mislead the public into thinking that many worthless or unproven treatments are effective.
Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel-but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology…
It is April 1st, 2038. Day 60 of China's blockade of the rebel island of Taiwan.
The US government has agreed to provide Taiwan with a weapons system so advanced that it can disrupt the balance of power in the region. But what pilot would be crazy enough to run…
I am the former president of Pfizer Global Research, where I led research groups around the globe in finding new medicines to treat cancer, addiction, AIDS, immunological diseases, and pain. After retiring from Pfizer, I have been closely involved with biotech companies that also are seeking breakthrough drugs. This industry is a crucial part of the healthcare ecosystem, as evidenced by the remarkable response and, ultimately, the crushing of the COVID-19 pandemic. Yet, it is not just underappreciated but is treated with scorn by many. This booklist provides sources from which the reader can gain a full understanding of the value of the biopharmaceutical industry, the challenges it faces, and its importance to the world’s health.
Legislators and healthcare insurers are seeking ways to slash healthcare costs, often focusing on cutting the costs of medicines through schemes like price controls. Yet, drugs make up only about 13 percent of the money paid on healthcare. This book does a great job of explaining what is behind the pricing of new drugs but, more importantly, shows that all life-saving drugs eventually become low-cost generics – truly a Great American Drug Deal.
This book scrutinizes all players in the healthcare industry and offers new ideas for cost-saving measures, such as closing loopholes, dealing with bad actors, and educating consumers. If you want to understand how best to balance innovation and affordability, this book is a must-read.
Developing life-changing drugs is risky and expensive—but that’s not what makes them unaffordable.Drug pricing is a staple of every news cycle and political debate. And while we’ve struggled for decades to agree on solutions that serve all patients without jeopardizing the invention of new medicines, many Americans suffer because they can’t afford the drugs they need.Do we really have to choose between affordability and innovation?In The Great American Drug Deal, scientist and industry expert Peter Kolchinsky answers this question with a decisive No. The pharmaceutical industry’s commitment to creating new lifesaving drugs destined to become inexpensive generics can be balanced…
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
A key issue about drug pricing not covered in Kolchinsky's book relates to value: even if a new therapy is affordable, is it "worth it"? Health economist Peter Neumann and his colleagues have written an authoritative, insightful, and extremely accessible history of efforts to align drugs' prices with their benefits to patients and society. This is a must-read guide for both insiders and non-experts to a topic that will be at the forefront of the drug pricing debate in the coming decade.
The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only…
The Year Mrs. Cooper Got Out More
by
Meredith Marple,
The coastal tourist town of Great Wharf, Maine, boasts a crime rate so low you might suspect someone’s lying.
Nevertheless, jobless empty nester Mallory Cooper has become increasingly reclusive and fearful. Careful to keep the red wine handy and loath to leave the house, Mallory misses her happier self—and so…
In my younger days, as the son of a medical professor and a public health nurse, I was more interested in healing society than patients. But my political interests and research agenda as a professor of political science ultimately led back to medicine. I found that profit-maximizing market competition in health care failed miserably to promote value in therapeutics and economize on society’s scarce resources. I became aware of the neglect of public health to prevent disease for vulnerable groups in society and save money as well as lives. Pervasive and enduring economic conflicts of interest in the medical-industrial complex bear primary responsibility for severe deficits in quality, equality, and economy in American health care.
I found, as a history buff, The Struggle for Drug Reform to be an eye-opener about how America’s exceptionally high drug prices among other deficits in health care quality and coverage resulted from the past exercise of power by the pharmaceutical industry, the lynchpin of America’s “medico-industrial complex.”
I was impressed by historian Tobbell’s meticulously researched account of the industry’s strategic alliances with self-interested medical scientists, not just conservative political forces, and its use of anti-communist propaganda to fight off the threat of drug pricing regulations.
I personally found important her discussions of how the industry allied with the American Medical Association against universal health care, against FDA demands for evidence about drug efficacy and safety before allowing drugs on the market, and against the threat to its profits from generic drugs.
Since the 1950s, the American pharmaceutical industry has been heavily criticized for its profit levels, the high cost of prescription drugs, drug safety problems, and more, yet it has, together with the medical profession, staunchly and successfully opposed regulation. "Pills, Power, and Policy" offers a lucid history of how the American drug industry and key sectors of the medical profession came to be allies against pharmaceutical reform. It details the political strategies they have used to influence public opinion, shape legislative reform, and define the regulatory environment of prescription drugs. Untangling the complex relationships between drug companies, physicians, and academic…
I am a medical thriller author who, during a brief stint in residency after medical school, saw up close what the world of medicine is really like, from the level of the patient at the bedside to the industrial level with big corporate players such as pharmaceutical and health insurance companies. I am in a position to curate what books can inform the general public about such topics.
If you already dislike the pharmaceutical industry for whatever reason, this book could certainly make your blood boil further.
In an effort to get a diverse perspective on Big Pharma, I made sure to check out a book with a contrary opinion, and this one fit the bill. I came away with a greater awareness of the industry’s impacts that are widespread globally, not locally.
In Pharmanomics, investigative journalist Nick Dearden digs down into the way we produce our medicines and finds that Big Pharma is failing us, with catastrophic consequences.
Big Pharma is more interested in profit than health. This was made clear as governments rushed to produce vaccines during the Covid pandemic. Behind the much-trumpeted scientific breakthroughs, major companies found new ways of gouging billions from governments in the West while abandoning the Global South. But this is only the latest episode in a long history of financialising medicine - from Purdue's rapacious marketing of highly addictive…
I am a medical thriller author who, during a brief stint in residency after medical school, saw up close what the world of medicine is really like, from the level of the patient at the bedside to the industrial level with big corporate players such as pharmaceutical and health insurance companies. I am in a position to curate what books can inform the general public about such topics.
I have always known that problems can potentially occur with pharmaceutical drugs, even when regulations are in place. But when there is a black market for dangerous counterfeit versions of those drugs, the risk to patient safety skyrockets.
I liked how this book opened my eyes to this global phenomenon that is more common than one might think.
Long the scourge of developing countries, fake pills are now increasingly common in the United States. The explosion of Internet commerce, coupled with globalization and increased pharmaceutical use has led to an unprecedented vulnerability in the U.S. drug supply. Today, an estimated 80% of our drugs are manufactured overseas, mostly in India and China. Every link along this supply chain offers an opportunity for counterfeiters, and increasingly, they are breaking in. In 2008, fake doses of the blood thinner Heparin killed 81 people worldwide and resulted in hundreds of severe allergic reactions in the United States. In 2012, a counterfeit…
Don’t mess with the hothead—or he might just mess with you. Slater Ibáñez is only interested in two kinds of guys: the ones he wants to punch, and the ones he sleeps with. Things get interesting when they start to overlap. A freelance investigator, Slater trolls the dark side of…
In my younger days, as the son of a medical professor and a public health nurse, I was more interested in healing society than patients. But my political interests and research agenda as a professor of political science ultimately led back to medicine. I found that profit-maximizing market competition in health care failed miserably to promote value in therapeutics and economize on society’s scarce resources. I became aware of the neglect of public health to prevent disease for vulnerable groups in society and save money as well as lives. Pervasive and enduring economic conflicts of interest in the medical-industrial complex bear primary responsibility for severe deficits in quality, equality, and economy in American health care.
I find Angell’sThe Truth About the Drug Companies extremely valuable for teaching students about how the pharmaceutical industry translates high profits into power resources to protect and increase those profits over time.
The former New England Journal of Medicine editor exposed how drug companies enlist politicians, the FDA, and medical academia for their cause. And armies of lawyers to extend monopoly marketing rights for years.
It was my first introduction to how they spend more on marketing than research, much of that on “copy-cat” drugs of dubious superiority to ones with expired patents.
As a tax (and high drug price) payer, I was disturbed to learn how they use government funds for basic research and then rig and spin their reporting of clinical studies to inflate their products’ therapeutic value and underplay their risks.
During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes…
I am an economist who came to realize that the marketplace of ideas was a political doctrine, and not an empirical description of how we came to know what we think we know. Science has never functioned in the same manner across centuries; it was only during my lifetime that it became recast as a subset of market reality. I have spent a fair amount of effort exploring how economics sought to attain the status of a science; but now the tables have turned. It is now scientists who are trained to become first and foremost market actors, finally elevating the political dominance of the economists.
A best-seller in the UK, it never garnered the attention it deserved in the US. As a trained physician, Goldacre explains why doctors cannot trust the information concerning prescription drugs that is made available to them, and why this should concern every patient. The incentives motivating drug regulators constitute a big part of the problem, but the actual conduct of clinical trials comes in for intensive scrutiny as well. The rigors of double-blinded trials are useless if owners of the data can hide whatever outcomes they don’t like. His chapter on how to bend a clinical trial has become a classic.
"Smart, funny, clear, unflinching: Ben Goldacre is my hero." ―Mary Roach, author of Stiff, Spook, and Bonk
We like to imagine that medicine is based on evidence and the results of fair testing and clinical trials. In reality, those tests and trials are often profoundly flawed. We like to imagine that doctors who write prescriptions for everything from antidepressants to cancer drugs to heart medication are familiar with the research literature about these drugs, when in reality much of the research is hidden from them by drug companies. We like to imagine that doctors are impartially educated, when in reality…
I am peculiar. Really. I’m an autistic, non-binary, PhD historian who writes mystery novels (The Framed Women of Ardemore House, The Dead Come to Stay) and weird non-fiction books (Mr. Humble and Dr. Butcher and The Intermediaries). But I also love to read, and among my friends are folks like Deanna Wraybourn (Killers of a Certain Age) and Chuck Wendig (Staircase in the Woods), Mary Roach (Stiff) and Deborah Blum (Poisoner’s Handbook). I wanted to share their work, too. That’s why I started the Peculiar Book Club YouTube and podcast: to be a home for authors and readers of the quirky, quizzical, curious, and bizarre. If you’re weird, you’re family.
Two pharmacists sit in a Boston courtroom accused of murder. The weapon: a fungus. The death count: 100 and rising. These facts set the stage for a true-crime thriller by investigative journalist Jason Dearen, and it has the makings of a horror movie. There’s scientific hubris, sketchy ethics, a cover-up, and a monster, too: a slimy, sticky, fungal mold that infected patients and began eating their brains alive. It’s riveting, packed with information about how fungal spores managed to contaminate a medical supply chain, and frankly hard to put down. I have done my share of forensic research, and never have I encountered killer fungus before; I consider this an unmissable book.
An award-winning investigative journalist's horrifying true crime story of America's deadliest drug contamination outbreak and the greed and deception that fueled it.
Two pharmacists sit in a Boston courtroom accused of murder. The weapon: the fungus Exserohilum rostratum. The death count: 100 and rising. Kill Shot is the story of their hubris and fraud, discovered by a team of medical detectives who raced against the clock to hunt the killers and the fungal meningitis they'd unleashed.
"Bloodthirsty" is how doctors described the fungal microbe that contaminated thousands of drug vials produced by the New England Compounding Center (NECC). Though NECC…
I am a medical thriller author who, during a brief stint in residency after medical school, saw up close what the world of medicine is really like, from the level of the patient at the bedside to the industrial level with big corporate players such as pharmaceutical and health insurance companies. I am in a position to curate what books can inform the general public about such topics.
Pharmaceutical drugs are not just about brand-name products with corporate exclusivity over them. There’s also the world of generic drugs, with multiple companies manufacturing the same drug, and even that part of the industry can have hidden dangers.
Besides this eye-opener about generic drugs, the book provides a focus on the efforts of one person investigating shady generic drug companies, providing the mild feel of a detective novel.
Kirkus Reviews Best Health and Science Books of 2019
Science Friday Best Books of 2019
New postscript by the author
From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale—The Jungle for pharmaceuticals
Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics,…
